CGONCG Oncology, Inc.
CG Oncology, Inc. (CGON) develops and commercializes targeted therapies for oncology, with a focus on advanced cancer treatments. The next catalyst is Nov 6, 2026 — Q3 2026 Earnings Release, which will test the company’s financial execution and clinical progress, particularly around the BOND-003 Phase 3 study.
- Revenue surged 254.7% YoY to $3.91M, but net income remains -$243.27M, with a net margin of -6,228.1%.
- Free cash flow (TTM) is -$314.90M, and debt-to-equity is 0.00x, reflecting a leveraged-free capital structure.
- Shareholders’ equity stands at $752.60M, with diluted EPS of -0.90.
The Read
8% on Q4 2025 earnings and BLA progress, then held steady after mixed Q1 results, rallied 8% avoiding a dilution offering, and spiked 10% on positive Phase 3 data and BLA submission timing.
The schedule
- Fri6Nov
CGON will report Q3 2026 earnings, which will test its P&L, product mix, and cash flow against revenue and loss expectations. The outcome will be critical for assessing the company's ability to meet its commercial readiness goals and manage its debt structure.
- Fri1Jan
This event will test the company's ability to maintain its financial performance and manage its debt structure, particularly in light of the recent Q2 loss and missed revenue estimates.
- Tue9Feb
This event will test the company's ability to meet its financial and operational goals, particularly in light of the recent Q2 loss and missed revenue estimates.
- Fri7May
This event will test the company's ability to meet its financial and operational goals, particularly in light of the recent Q2 loss and missed revenue estimates.
Past
- Fri7Aug
Actual outcome: Bull · $76.99 at outcome
CG Oncology reported Q2 earnings with an EPS of -$0.71, which met consensus estimates. The stock rallied past the bull target as investors focused on the company's clinical progress, specifically the strong efficacy and safety data for cretostimogene grenadenorepvec in NMIBC and the anticipated completion of its rolling BLA submission in Q4 2026.
- Wed15Jul
Actual outcome: Bull · $71.83 at outcome
CG Oncology avoided a dilutive follow-on equity offering, as updates confirmed the company maintains a strong cash position sufficient to support operations through 2029. The stock reached the bull target, driven by this financial stability alongside encouraging phase II data for cretostimogene and its planned 2026 BLA filing.
- Fri8May
Actual outcome: Bull · $72.04 at outcome
CG Oncology delivered mixed Q1 2026 results, posting a revenue beat alongside an earnings per share loss that met or slightly missed estimates. Although analysts boosted their forecasts following the print and the company announced upcoming Phase 2 trial presentations at the AUA Annual Meeting, the mixed financial performance resulted in a flat price reaction, leaving the stock hovering between bull and bear targets.
